On the other hand, the manufacturers indicate that in highly active MS IFN-β discontinuation during pregnancy should be critically weighted up against the risk of severe relapses and there are several reports showing no detrimental effects when IFN-β and GA were continued during pregnancy [25], [26]. Here, IFNB1 is linked to myeloid sarcoma.